Company Description
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, develops allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses in the United States.
Its product pipeline comprises CLD-101, which is in Phase 1b/2 clinical trial for the treatment of high-grade glioma, and Phase 1, dose-escalation clinical trial for NNV1 in patients with newly diagnosed high-grade gliomas; CLD-201 product for solid tumors, such as breast cancer, head and neck squamous cell carcinoma, and soft tissue sarcoma, which is in pre-clinical studies; CLD-301) for multiple indications in preclinical studies; and CLD-400 for certain lung cancer and metastatic solid tumors.
The company also offers NeuroNova, an oncolytic virus platform; and SuperNova platform. Calidi Biotherapeutics, Inc. is headquartered in San Diego, California.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Eric Poma |
Contact Details
Address: 4475 Executive Drive, Suite 200 San Diego, California 92121 United States | |
| Phone | 858 794 9600 |
| Website | calidibio.com |
Stock Details
| Ticker Symbol | CLDI |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001855485 |
| CUSIP Number | 320703309 |
| ISIN Number | US3207033099 |
| Employer ID | 86-2967193 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Eric E. Poma Ph.D. | Chief Executive Officer and Director |
| Andrew C. Jackson | Chief Financial Officer |
| Wendy Pizarro Campbell Esq. | Chief Legal, Chief Corporate Dev, Chief Diversity and Corp Secretary |
| Dr. Boris Minev M.D., Ph.D. | President of Medical and Scientific Affairs |
| Dr. Antonio Fernandez Santidrian Ph.D., Pharm.D. | Head of Technical Operations and Chief Scientific Officer |
| Guy Travis Clifton M.D. | Chief Medical Officer, Consultant and Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 12, 2025 | PRE 14A | Other preliminary proxy statements |
| May 2, 2025 | 8-K | Current Report |
| Apr 23, 2025 | 8-K | Current Report |
| Apr 10, 2025 | 8-K | Current Report |
| Apr 1, 2025 | 8-K | Current Report |
| Mar 31, 2025 | 8-K | Current Report |
| Mar 31, 2025 | 10-K | Annual Report |
| Mar 31, 2025 | 424B5 | Filing |
| Mar 10, 2025 | 8-K | Current Report |
| Feb 10, 2025 | 8-K/A | [Amend] Current report |